Abstract. ANRIL, a large antisense non-coding RNA, is in the proximity of CDKN2A and overlapped with CDKN2B at human chromosome 9p21, and has been strongly implicated in the association with high risk genetic markers of coronary artery disease (CAD). Mice model harboring large deletion of posterior part of ANRIL and CAD high risk genetic markers resulted in substantial suppression of both CDKN2A and CDKN2B; however, the mechanistic insights of regulation and function of ANRIL have remain elusive. To date multiple splice variants of ANRIL have been reported and expression of specific splice variant of ANRIL has been shown to be tightly associated with 9p21 CAD high risk markers. Here we identified a new splice variant of ANRIL and introduced it into HeLa cells to uncover functional aspects of ANRIL towards cellular function. For this purpose, we monitored global mRNA expressional changes and conducted gene ontology enrichment. The majority of mRNAs was downregulated by ANRIL overexpression. Among them, a subset of mRNAs particularly involved in the regulation of nucleus and establishment or maintenance of chromatin architecture was significantly enriched. Such a circumstance was manifested after 48 h of ANRIL overexpression but no significant changes were seen after 24 h of ANRIL overexpression. Next we analyzed the sequences containing the intergenic region between ANRIL and CDKN2A (p14ARF) by introducing the sequences upstream of luciferase reporter gene. Based on the luciferase activity, the sequences tested were shown to act as promoter for ANRIL and p14ARF. Moreover, as well p14ARF, ANRIL promoter was responsive to transcription factor E2F1 in HeLa and A549 cells. Taken together, our present results indicate that co-regulation of ANRIL and p14ARF could be coupled by their unique intergenic region potentially through E2F1. Judged from the suppressive effect of ANRIL on a subset of mRNAs involved in the nuclear function suggests that ANRIL might have silencing effect on a specific gene set that accounts for a wide array of gene expression.
Introduction
The INK4/ARF locus at human chromosome 9p21 region has been implicated in tumorigenesis such as melanoma (1) . The region harbors CDKN2A (p16INK4a and p14ARF; partially overlapped transcripts that use different reading frame by alternative promoter) and CDKN2B (p15INK4b), and these tumor suppressor genes have been shown to be frequently mutated, deleted or aberrantly methylated in various human cancer specimens (2, 3) . Modeling of such phenomena in mice has shown to be resulted in tumor-prone phenotype (4) . Recently large antisense non-coding RNA in the INK4/ ARF locus (ANRIL, alias CDKN2BAS) was found within the 403-kilobase (kb) germ line deletion of a French family with a history of melanoma and neural system tumors (5) . Moreover, high susceptibility locus for coronary artery disease (CAD) in four European populations has been associated with haplo-type block spanning approximately 53-kb including the posterior part of ANRIL (6) .
One common single nucleotide polymorphism (SNP) linked to atherosclerosis, which is used as a synonym of CAD, was mapped to linkage disequilibrium (LD) region overlapped with posterior part of ANRIL, and genotype associated with increased risk for CAD was shown to be strongly correlated with decreased expression level for ANRIL, CDKN2A and CDKN2B in peripheral blood T cells (7) . In addition, based on five different microarray data, risk allele of one SNP located within 9p21 CAD risk locus has been shown to be associated with correlated expression pattern among ANRIL, CDKN2A and CDKN2B. Notably, within the same 9p21 CAD risk locus, conserved sequence has been shown to have enhancer activity by reporter gene assay (8) . Moreover, homozygous risk allele within the conserved sequence has been revealed to be associated with the increased reporter activity, and also responsible for expression pattern of ANRIL splice variants and CDKN2B expression level (8) . Results from another study demonstrated that risk haplotype of 9p21 CAD locus selectively increased the expression level of specific ANRIL variant in peripheral blood mononuclear cells and this was directly related to the severity of atherosclerosis (9) .
Recently solid evidence of a relationship between CADassociated SNPs located within a 58-kb LD block on human chromosome 9p21 and expression level for neighboring genes was demonstrated by mouse model with targeted deletion of orthologous 70-kb non-coding interval on mouse chromosome 4 (10) . In mice with 70-kb targeted deletion, cardiac expression of Cdkn2a and Cdkn2b were greatly suppressed, and expectedly, increased cell proliferation and deregulated senescence were observed (10) . Collectively, the evidence suggests that ANRIL is involved in the regulation of neighboring genes such as CDKN2A and CDKN2B, and function of ANRIL is likely to be executed through coregulated gene products; however, regulation and function of ANRIL is not yet fully understood.
Here we identified a novel splice variant of ANRIL and expressed it into HeLa cells. By conducting microarray and gene ontology enrichment analysis, we revealed that overexpression of ANRIL has a strong tendency to suppress mRNA expression particularly involving regulation of the nucleus. We also analyzed the sequences containing intergenic region of human ANRIL and CDKN2A (p14ARF), and to our knowledge, this is a first experimental demonstration that the sequences containing the intergenic region of ANRIL and p14ARF potentially is under control of cell cycle and the apoptosis regulator E2F1.
Materials and methods
Cells, plasmids and transfection. HeLa (cervical carcinoma) and A549 (lung adenocarcinoma) cells were cultured in Earle's modified Eagle's medium (Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine serum, 1% non-essential amino acids (Invitrogen) and antibiotic-antimycotics (Invitrogen). Homo sapiens cDNA clone L6ChoCKO-2-E10 5' (GenBank Accession No. CB109081) was provided by Functional Genomic Research Center, Korean Research Institute of Bioscience and Biotechnology. Cells were plated into 60 mm dishes 24 h prior to transfection and 2 μg of plasmid was transfected for ANRIL overexpression by using Lipofectamine Plus (Invitrogen) according to the manufacturer's instructions.
Promoter fragments were generated with the polymerase chain reaction (PCR) method from human genomic DNA (Promega, Madison, WI), and ligated into the respective enzyme KpnI and HindIII sites of pGL3-Basic vector (Promega). PCR primers were designed on public genome sequence (GenBank No. AL449423) as follows (underlines indicate flanking enzyme site); ANRIL-851, GGGGTACCTG TGTGAAGGGAGGTCCAGG; ANRIL+29, CCCAAGCTTA GGGCCGTGTCAGGTGACG; p14ARF-388, GGGGTACC GGAATAGGGGAGCGGGGACG; p14ARF+22, CCC AAGCTTGCGCACCCGCCTTCCCTGAG, where minus position is relative to transcriptional start site as +1, which is identical to the 5'-end of ANRIL (GenBank Accession Version No. NR_003529.3) and p14ARF (GenBank Accession No. NM_058195), respectively. All the plasmid sequences were verified by sequencing at the Takara facility (Mie, Japan). In pGL3-p14ARF -388/+22, -175C was changed to -175T. pcDNA3 and pcDNA3-E2F1 has previously been described (11) .
Luciferase reporter assay. For the promoter assay, 2x10 4 cells were transfected with FuGene6 (Roche, Basel, Switzerland), in accordance with the manufacturer's instructions. Briefly, 200 ng of the expression plasmid, 200 ng of the firefly luciferase reporter plasmids pGL3-Basic (Promega) and 0.6 ng of the Renilla luciferase reporter plasmid pRL-TK (Promega) per 24-well dish were used for each transfection. Cells were lysed 24 h after transfection by applying 100 μl passive lysis buffer of the Dual Luciferase Reporter Assay kit (Promega) into each well of the 24-well plate. Five microliters of cell lysate was used for the luciferase reporter assay with the same kit according to the manufacturer's protocol. Light intensity was quantified in a GloMax 20/20n Luminometer (Promega). Experiments were performed at least in triplicate. As control for the transfection efficiency, the firefly luciferase activity values were normalized to the Renilla luciferase activity values. Data are presented as mean values ± SD. Statistical differences were analyzed using two-tailed Student's t-tests. A value of P<0.05 (n=3) was considered to indicate a statistically significant difference.
Real-time reverse transcription-PCR (RT-PCR).
Total RNA (500 ng) was used for cDNA synthesis by PrimeScript RT (Takara, Otsu, Japan) with random 6-mers primer. SYBR Premix Ex Taq (Takara) was used for real-time PCR with primers in exons 17 and 18 (6) . Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was detected and its mRNA level was used as a control.
Microarray analysis. Whole Human Genome oligoDNA microarray (Agilent Technologies, Santa Clara, CA; 4x44k platform) was used. Procedure for microarray analysis was performed according to manufacturer's standard protocol. Briefly, Cy3-labeled cRNA was synthesized by Low RNA Input Fluorescent Linear Amplification kit (Agilent). For data normalization, 75 percentile normalization using a perchip 75 percentile of all measurements were performed. Duplicate and triplicate analyses were done for 24 and 48 h after transfection samples, respectively.
Results

Identification of a new splice variant of ANRIL and its effect on global gene signature. It has been shown that ANRIL gene spans ~130-kb and is consisted of 19 exons (5).
In silico analysis has originally identified large (3834-bp, GenBank Accession No. DQ485453), which is considered as full-length and small (2659-bp, GenBank Accession No. DQ485454) ANRIL variants (5). We initially searched for other ANRIL splice variants in the public database. The sequence of L6ChoCKO-2-E10 5' (GenBank Accession No. CB109081) cDNA was identical to exon 1 and 5' part of exon 2 of ANRIL. Thus we determined the full-length sequence of the clone and revealed it encodes a new splice variant of ANRIL with poly(A), composed of exons 1, 2, 4-7, and alternatively spliced new exon located in intron 12, and 13-19 (Fig. 1A) . The 2177-bp length new variant of ANRIL (GenBank Accession No. AB548314) has neither apparent open reading frames with longer size nor similarities with annotated proteins. This splice variant is different from previously reported 8 variants of ANRIL (12) .
It has been widely recognized that non-coding RNAs are involved in the wide array of transcriptional networks (13) . Therefore, we asked whether new splice variant of ANRIL has any effect on gene expression signatures. To accomplish this, we expressed ANRIL new splice variant into HeLa cells, and total RNAs were recovered for gene expression changes checked by microarray analysis. A new variant is originally cloned in pCNS-D2 that has CMV promoter up-stream of ANRIL cDNA. After 48 h of transfection, relative expression level of ANRIL/GAPDH mRNA was estimated over 10000-fold by real-time RT-PCR in ANRIL-transfected cells compared to control-transfected cells (Fig. 1B) . Among 41035 transcripts, uniformly-detected 39859 transcripts were selected based on the criteria of per-prove CV (coefficient of variation) <50%. Next 248 transcripts were selected as they showed >2-fold changes and probability value (P-value) <0.05 (n=3) with no correction. They are shown as green spots in scatter plot as 235 mRNAs for down-regulated and 13 mRNAs for up-regulated in ANRIL overexpressed cells compared to Table I . Top-five-ranked GO annotation affected by ANRIL overexpression. 
Selection, 94 genes with GO annotation that showed expressional differences between control and ANRIL transfected HeLa cells. Total, 15448 genes with GO annotation that was used for GO enrichment analysis. Count, gene number included in GO accession. % Count, percentage of gene number included in selection or total. P-value, statistically significant difference of % count between selection and total. Table II . The genes annotated as GO term 'nucleus'. ----------------------------------------------------------------------------------------------------- control cells (Fig. 1C, right panel) . In contrast to 48 h after ANRIL transfection, no significant changes (n=2) were observed after 24 h after ANRIL transfection (Fig. 1C, left  panel) . Expression levels for CDKN2A and CDKN2B were unchanged by ANRIL overexpression.
-----------------------------------------------------------------------------------------------------
-----------------------------------------------------------------------------------------------------GenBank/ Ensembl no. Gene symbol Description Fold change Regulation -----------------------------------------------------------------------------------------------------
Subsequently gene ontology (GO) enrichment analysis was performed on GO annotation given genes (15448 out of 39859 and 94 out of 248 genes, respectively). Among the ANRIL-regulated mRNAs, GO terms with >5 gene numbers and P-value ≤0.01 were selected as top-five-ranked GO terms with low P-value (Table I) . As top-ranked GO category, 7 out of 94 genes (count in selection) and 269 out of 15448 genes (count in total) were included in 'establishment or maintenance of chromatin architecture'. This means 7.4% (7/94) for % count in selection and 1.7% (269/15,448) for % count in total, respectively (Table I) . Seven genes annotated as GO term 'establishment or maintenance of chromatin architecture' were all included in GO term 'nucleus'. Thirtyeight genes with GO term 'nucleus' were listed; 36 were down-regulated and 2 were up-regulated by ANRIL (Table II) . Taken together, these results suggest that new splice variant of ANRIL has suppressive effect on genes involved in the regulation of nucleus and this effect could be maximized at 48 h after transfection in HeLa cells.
Characterization of intergenic region of ANRIL and CDKN2A
by luciferase reporter assay. Pasmant et al have predicted that ANRIL and p14ARF may share a bidirectional promoter (5), but no experimental demonstration has been performed. Therefore, we attempted to analyze the promoter activity surrounding the intergenic region of ANRIL and p14ARF. For this purpose, we amplified the putative promoter region of ANRIL encompassing the -851 to +29 region (-851/ +29), in which the transcriptional start site of ANRIL was designated as +1, using PCR and then cloned it into a pGL3-Basic luciferase reporter plasmid (Fig. 2A) . The amplified region contained three E2F binding sites, as predicted using Transfac software when the threshold was set to 85 ( Fig. 2A) . The pGL3-ANRIL -851/+29 reporter showed an ~4-fold induction of luciferase activity, compared with that in pGL3-Basic, in HeLa cells (Fig. 2B) . Co-transfection of E2F1 with pGL3-ANRIL -851/+29 reporter showed an ~4-fold induction of luciferase activity, compared with that in pcDNA3 cotransfection, in HeLa cells (Fig. 2B) . In A549 cells, almost the same basal promoter activity and E2F1 regulation was confirmed (Fig. 2C ). An E2F binding site located within the intergenic region alone could be responsive to E2F1, indicating that one E2F binding site recognized in the intergenic region might have been bound by E2F1 (unpublished data). The p14ARF promoter has been well characterized as E2F1-regulated gene promoter (14) . As a positive control for E2F1-dependent promoter regulation, we constructed p14ARF promoter-luciferase reporter, named pGL3-p14ARF -388/+22 ( Fig. 2A) , and the basal promoter activity was ~5-fold, compared with that in pGL3-Basic and luciferase activity was 9-fold up-regulated by E2F1 co-expression in HeLa cells (Fig. 2D) . Collectively, these results demonstrated that the intergenic region could act as a bidirectional promoter and interactively regulated by E2F1 towards ANRIL and p14ARF gene direction.
Discussion
Implication of ANRIL in 9p21-associated human disease has been widely reported (5) (6) (7) (8) (9) (10) 12, 15) ; however, any func-tional and mechanistic clues have yet to be determined largely due to non-coding feature of ANRIL. Here, we identified a new splice variant of ANRIL and introduced it into HeLa cells, and this resulted in a significant suppression of mRNAs involved in the regulation of nuclear function. Moreover, we constructed luciferase reporter for ANRIL promoter and revealed that ANRIL as well as p14ARF could be regulated by E2F1.
ANRIL and p14ARF are adjacent to each other and showed stronger similar expression pattern in normal human tissues and breast tumors compared to those of p16INK4a and p15INK4b (5) . In the present study, we focused on ANRIL and p14ARF because the two genes are overlapped by just 299-bp. The intergenic region was proven to be a bidirectional promoter and co-regulated by E2F1. It has been shown that p19ARF, a mouse version of human p14ARF, is a direct transcriptional target of E2F1, and in turn, p19ARF (p14ARF) negatively regulate E2F1, thus forming a negative feedback loop (16) (17) (18) . Based on the finding that ANRIL overexpression in HeLa cells led to the suppression of mRNAs involved in nuclear function, we tested whether ANRIL has any effect on E2F1-and p53-dependent transcriptional regulation, but no effect was found (unpublished data). Generally, promoters of long non-coding RNAs have been shown to be regulated by transcriptional factors such as Oct3/4, Nanog, CREB, Sp1, c-Myc, Sox2, NF-κB and p53 and marked with epigenetic histone modifications (19) . Indeed, intergenic region between ANRIL and p14ARF was shown to be bound by CTCF, which possesses insulator and chromatin barrier activity, and CTCF activity and DNA methylation status were responsible for co-expression of ANRIL and p14ARF (20) . Liu et al have reported that common allele of CAD susceptibility SNP that is approximately 120-kb distant from ANRILp14ARF intergenic region could affect the expression level of ANRIL, p14ARF, p16INK4a and p15INK4b in peripheral blood T cells (7) . Therefore, our reporter plasmid could be useful to test whether enhancer sequences identified within 9p21 CAD susceptibility locus has synergistic effect on the promoter activity of ANRIL-p14ARF intergenic region.
The high-risk CAD haplotype has been shown to be associated with exons 13-19 of ANRIL (6, 8) . A new ANRIL variant used in this study also possesses exons 13-19, suggesting the new variant could represent high-risk CAD haplotype, but precise expression pattern of this new variant in cells or tissues affected by atherosclerosis should be further determined. Among ANRIL-regulated mRNAs, downregulated mRNAs were majority compared to up-regulated mRNAs; however, our present results may represent a limited function of ANRIL variant because ANRIL has been shown to have multiple variants in tissue or cell-type specific manner (12) . In addition, processing of ANRIL such as producing of mature microRNA and small peptide should be verified in a near future to fully understanding of molecular mechanism of ANRIL.
In conclusion, ANRIL and CDKN2A (p14ARF) are physically linked by the intergenic region and co-regulated by E2F1. The finding of suppressive effect of ANRIL on genes involved in the regulation of nuclear events could contribute to piece together details of ANRIL underlying human 9p21-associated pathogenesis.
